MA30000B1 - Nouvelle forme cristalline d'un derive de pyridazino [4,5-b] indole - Google Patents

Nouvelle forme cristalline d'un derive de pyridazino [4,5-b] indole

Info

Publication number
MA30000B1
MA30000B1 MA30757A MA30757A MA30000B1 MA 30000 B1 MA30000 B1 MA 30000B1 MA 30757 A MA30757 A MA 30757A MA 30757 A MA30757 A MA 30757A MA 30000 B1 MA30000 B1 MA 30000B1
Authority
MA
Morocco
Prior art keywords
pyridazino
crystalline form
novel crystalline
indole derivative
indole
Prior art date
Application number
MA30757A
Other languages
English (en)
Inventor
William L Rocco
John D Higgins
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30000(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of MA30000B1 publication Critical patent/MA30000B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne une nouvelle forme cristalline de 7-chloro-N,N,5-triméthyle-4-oxo-3-phényle- 3,5-dihydro-4H-pyridazino[4,5--]indole-1-acétamide, des procédés de préparation de cette forme cristalline de 7-chloro-N,N,5-triméthyle-4-oxo-3-phényle-3,5-dihydro-4H-pyridazino[4,5-o]indole-1-acétamide, des compositions contenant cette forme mélangée à un ou plusieurs excipients acceptables sur le plan pharmaceutique, et utilisations associées.
MA30757A 2005-08-29 2008-03-17 Nouvelle forme cristalline d'un derive de pyridazino [4,5-b] indole MA30000B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29

Publications (1)

Publication Number Publication Date
MA30000B1 true MA30000B1 (fr) 2008-12-01

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30757A MA30000B1 (fr) 2005-08-29 2008-03-17 Nouvelle forme cristalline d'un derive de pyridazino [4,5-b] indole

Country Status (31)

Country Link
US (1) US7683062B2 (fr)
EP (1) EP1924585B1 (fr)
JP (1) JP5063600B2 (fr)
KR (2) KR20080050577A (fr)
CN (1) CN101253176B (fr)
AR (1) AR057099A1 (fr)
AT (1) ATE531717T1 (fr)
AU (1) AU2006285142B2 (fr)
BR (1) BRPI0615259A2 (fr)
CA (1) CA2619284C (fr)
CR (1) CR9723A (fr)
CY (1) CY1112317T1 (fr)
DK (1) DK1924585T3 (fr)
EA (1) EA014164B1 (fr)
EC (1) ECSP088209A (fr)
ES (1) ES2375841T3 (fr)
HR (1) HRP20120073T1 (fr)
IL (1) IL189276A (fr)
MA (1) MA30000B1 (fr)
NO (1) NO20081365L (fr)
NZ (1) NZ566087A (fr)
PL (1) PL1924585T3 (fr)
PT (1) PT1924585E (fr)
RS (1) RS52318B (fr)
SI (1) SI1924585T1 (fr)
TN (1) TNSN08059A1 (fr)
TW (1) TW200813060A (fr)
UA (1) UA91716C2 (fr)
UY (1) UY29771A1 (fr)
WO (1) WO2007027525A1 (fr)
ZA (1) ZA200801890B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687308B1 (fr) * 2003-11-17 2019-06-12 Merck & Cie Procédé pour la préparation de la forme cristalline B de (6R)-L-érythrotetrahydrobioptérin hydrochloride a partir d'autres formes cristallines
WO2005118586A1 (fr) * 2004-06-02 2005-12-15 Sandoz Ag Intermediaire de meropenem sous forme cristalline
BRPI0616040A2 (pt) * 2005-09-21 2011-06-07 Nycomed Gmbh cloridrato de sulfonilpirról como inibidor de histona desacetilases
EP2404911A1 (fr) * 2005-10-31 2012-01-11 Janssen Pharmaceutica NV Nouveaux procédés pour la préparation de dérivés de pipérazinyle et diazépanyle benzamide
CA2656057C (fr) * 2006-06-16 2012-10-02 H. Lundbeck A/S Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique
CA2667345C (fr) * 2006-10-27 2016-03-22 Signal Pharmaceuticals, Llc Formes solides comprenant un compose de 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions contenant celles-ci et utilisation de celles-ci
EP2085397A1 (fr) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Forme cristalline d'abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
CA2734448A1 (fr) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Methode de preparation d'un polymorphe du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4h-pyridazino[4,5-b]indole-1-acetamide
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
JP2013536859A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストの非吸湿性塩
EP2760859A1 (fr) * 2011-09-30 2014-08-06 Sunshine Lake Pharma Co., Ltd Formes cristalline d'azilsartan et leur préparation et leurs utilisations
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
KR20170139074A (ko) 2015-04-24 2017-12-18 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2017079678A1 (fr) 2015-11-04 2017-05-11 Omeros Corporation Formes solides d'un inhibiteur de pde10
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
US20050220881A1 (en) 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
KR20080050577A (ko) 2008-06-09
KR20130087059A (ko) 2013-08-05
JP2009506116A (ja) 2009-02-12
TNSN08059A1 (en) 2009-07-14
AU2006285142A1 (en) 2007-03-08
UY29771A1 (es) 2007-03-30
PT1924585E (pt) 2012-01-19
DK1924585T3 (da) 2012-02-27
NO20081365L (no) 2008-04-03
CN101253176B (zh) 2012-04-18
WO2007027525A1 (fr) 2007-03-08
CY1112317T1 (el) 2015-12-09
PL1924585T3 (pl) 2012-08-31
CA2619284A1 (fr) 2007-03-08
CR9723A (es) 2008-06-18
EP1924585A1 (fr) 2008-05-28
SI1924585T1 (sl) 2012-09-28
CN101253176A (zh) 2008-08-27
NZ566087A (en) 2011-03-31
EP1924585B1 (fr) 2011-11-02
US7683062B2 (en) 2010-03-23
ATE531717T1 (de) 2011-11-15
AR057099A1 (es) 2007-11-14
HRP20120073T1 (hr) 2012-07-31
JP5063600B2 (ja) 2012-10-31
IL189276A (en) 2012-07-31
UA91716C2 (ru) 2010-08-25
EA014164B1 (ru) 2010-10-29
ZA200801890B (en) 2009-11-25
BRPI0615259A2 (pt) 2011-05-17
ES2375841T3 (es) 2012-03-06
IL189276A0 (en) 2008-08-07
AU2006285142B2 (en) 2012-06-14
TW200813060A (en) 2008-03-16
ECSP088209A (es) 2008-06-30
RS52318B (sr) 2012-12-31
CA2619284C (fr) 2014-04-29
EA200800716A1 (ru) 2008-08-29
HK1123794A1 (en) 2009-06-26
US20080139569A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MA30000B1 (fr) Nouvelle forme cristalline d'un derive de pyridazino [4,5-b] indole
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
MY129348A (en) Stable polymorph of n-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4- quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
DE60015153D1 (de) Isomere kondensierte pyrrolocarbazole und isoindolone
DE60326060D1 (de) Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung
PL1776349T3 (pl) Pochodne 2-amino-chinazoliny użyteczne jako inhibitory beta-sekretazy (BACE)
UA93043C2 (ru) ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ ТРАНС-5-ХЛОР-2-МЕТИЛ-2,3,3А,12В-ТЕТРАГИДРО-1Н-ДИБЕНЗ[2,3:6,7]ОКСЕПИНО[4,5-с]ПИРОЛА
EE200000048A (et) Uudsed ühendid
ZA200309626B (en) Oxytocin Agonists.
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
PL1966198T3 (pl) Pochodne 2-amino-3,4-dihydropirydo[3,4-d]pirymidyny do zastosowania jako inhibitory beta-sekretazy (BACE)
YU62504A (sh) Triciklična 2-pirimidonska jedinjenja korisna kao inhibitori hiv reverzne transkriptoze
MX2007005478A (es) Formulaciones de derivados de [1,4]diazepino[6,7,1-ij]quinolina.
NZ530587A (en) Diazacycloalkanes as oxytocin agonists
MXPA04000358A (es) Hexahidroazepino (4,5-g) indoles e indolinas como ligandos del receptor 5-ht.
NO20061575L (no) Fremgangsmate for fremstilling av renzapride og mellomprodukter derav
TW200626600A (en) Octahydropyrrolo[3, 4-c]pyrrole derivatives
TW200518742A (en) Entry inhibitors
YU3203A (sh) Jedinjenja tricikličnog 2-piridona koja se koriste kao inhibitori hiv reverznih transkriptaza
MA28179A1 (fr) Nouveau compose, compositions correspondantes, methodes de fabrication et/ou de traitement
MY136138A (en) Hexacyclic compounds
TW200710091A (en) (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
WO2004014294A3 (fr) Indoles 4,7-disubstitues et procede de preparation